What Akis treats: main uses and benefits

Akis contains the active substance diclofenac sodium, which belongs to a group of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs). These medications are primarily used to reduce pain and inflammation in the body.

Therapeutic Indications

This medication is specifically formulated for administration via injection and is indicated for the treatment of various acute conditions where rapid relief is required. These include:

• Acute Flare-ups of Joint and Muscle Pain: Effective for sudden episodes of pain associated with osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis.
• Back Pain: Relief of acute lower back pain or spinal discomfort.
• Renal Colic: Management of the intense pain caused by kidney stones.
• Post-operative Pain: Short-term treatment of pain following surgical procedures.
• Traumatic Pain: Relief of pain resulting from injuries, such as fractures or severe sprains.

Mechanism of Action

Akis works by inhibiting the production of prostaglandins, which are chemicals in the body that signal pain and promote inflammation. by lowering the levels of these substances, the medication helps to decrease swelling and alleviate the sensation of pain.

Expected Benefits

The primary benefit of this treatment is the rapid onset of analgesic (pain-relieving) and anti-inflammatory effects. Because it is administered as an injection, it bypasses the digestive system, allowing the active ingredient to enter the bloodstream quickly. This makes it particularly useful for patients who are unable to take medications by mouth or those who require immediate stabilization of severe acute pain.

This information is strictly based on official regulatory documents for the active substance, diclofenac sodium injection.

Eligibility Status Summary

Populations Who Must Not Use This Medicine (Contraindications)

Akis is strictly contraindicated for use in individuals with the following conditions, as stated in authoritative labeling:

• Hypersensitivity: Known allergy to diclofenac or a history of asthma, hives, or allergic-type reactions after taking aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
• Gastrointestinal Disease: Active gastrointestinal bleeding, ulceration, or perforation, or a history of recurrent peptic ulcer/hemorrhage.
• Severe Organ Impairment: Severe hepatic (liver) failure or severe renal (kidney) failure (e.g., GFR <15 mL/min/1.73 m^2).
• Cardiovascular Disease: Established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• Pregnancy and Surgery: Use during the last trimester of pregnancy and for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age-Related Eligibility

The medicine is not approved for use in the pediatric population (children and adolescents). For the elderly, official documents recommend using the lowest effective dose for the shortest possible duration.

The official interaction profile of Akis (Diclofenac) is defined by its potential to interact with several classes of medicinal products, primarily through pharmacodynamic or pharmacokinetic mechanisms, as documented in government regulatory labeling.

Interaction Classifications and Restrictions

The most serious regulatory constraint involves combinations that are formally contraindicated or prohibited due to heightened risk. This includes concurrent use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including Aspirin at analgesic doses, and its use for peri-operative pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery [2.1, 4.3].

Co-administration with Diuretics or ACE Inhibitors/ARBs is documented to increase the risk of renal impairment and can diminish the antihypertensive or diuretic effects [4.5]. The use of alcohol is strongly associated with an increased risk of serious gastrointestinal events [1.4]. Regulatory information also notes that Elderly Patients are at a greater risk for serious GI adverse events when these PD interactions occur [4.3].

Primary Molecular Action: Inhibition of Cyclooxygenase (COX) Enzymes

The mechanism of action centers on the competitive inhibition of the Cyclooxygenase ( COX) enzyme system, which exists primarily as the COX-1 and COX-2 isoforms. By blocking the active sites of these enzymes, the drug prevents the conversion of Arachidonic Acid into various prostaglandins and related lipid mediators. This initial molecular step modulates the subsequent inflammatory response cascade.

Cascade Effect: Attenuation of Prostaglandin-Mediated Signaling

The resulting suppression of prostaglandin synthesis affects several physiological pathways, including those involved in nociception and thermoregulation. Reduced levels of PGE2 and PGI2 lead directly to the desensitization of nociceptors (peripheral nerve endings) and a modification of the central thermoregulatory set point in the brain. This mechanism modulates signaling associated with peripheral nerve endings and central thermoregulation.

Physiological Consequence: Modulation of Systemic Responses

The core physiological result of this mechanism is the limitation of excessive mediator activity, influencing responses at the tissue and systemic level. By reducing the chemical signals that increase local vascular permeability, the drug induces physiological adjustments that influence the overall effect profile.

Administration Guidelines for Akis Injection

Akis (diclofenac) is a ready-to-use solution that must only be administered by a healthcare professional via injection for short-term, acute pain management. The following guidelines describe the administration protocol.

Dosage and Route

Procedural Steps

• Intramuscular (IM): The 75 mg dose is administered by deep injection into the upper outer quadrant of the buttock. If a second 75 mg dose is required after at least six hours, the alternative buttock must be used for injection.
• Intravenous (IV) Infusion: The solution must not be given as an IV bolus injection (a rapid injection). It must be diluted immediately before use with 100–500 mL of a compatible solution (e.g., 0.9% sodium chloride or 5% glucose solution) that has been buffered with sodium bicarbonate. The infusion is then typically administered continuously over a period of 30 minutes to 2 hours.
• Preparation: The ampoule solution is ready-to-use and should not be diluted for intramuscular injection. Follow buffering and dilution instructions strictly for intravenous infusion.

These instructions define a controlled parenteral administration protocol, outlining precise dosing limits and procedural requirements for short-term use in adults, ensuring adherence to the maximum daily dose of 150 mg over a maximum two-day period.

Research evidence / Overview of Studies for Akis

Evidence for Acute Visceral Pain (Renal and Biliary Colic)

Akis injection was evaluated in research exploring conditions characterized by acute or disruptive episodes, such as renal colic (kidney stones) and biliary colic (gallbladder issues). Research exploring short-term symptom changes primarily involved Randomized Controlled Trials (RCTs) and systematic reviews, which compared parenteral Diclofenac to placebo or other pain medications in adult populations. These trials focused on patient-reported outcomes describing perceived discomfort. Studies reported how symptoms evolved in the observed populations over the first few hours of administration. Research highlights changes measured during the study period, but follow-up durations were limited, meaning long-term effects are not fully established or characterized by the acute trials. Data for certain groups remain insufficient, especially for patients presenting with certain underlying health issues.

Evidence for Acute Musculoskeletal and Postoperative Pain

Akis was evaluated in research contexts involving fluctuating or unstable symptoms related to acute discomfort, including post-operative pain and acute periods of heightened symptoms associated with inflammatory joint conditions. These studies typically involved RCTs and network meta-analyses that examined the systemic administration of the medication in adult patients. Studies explored the patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level during the study period. These studies contribute to understanding symptom patterns in populations where symptoms may vary in intensity. Follow-up durations were limited in many trials, particularly those using single or short-course injections, which means research provides insight into short-term changes but not long-term maintenance or sustained benefit. Evidence quality varies across studies, and direct comparisons against all potential active comparators may be uncertain due to differences in trial design.

Analysis of Long-Term Studies and Follow-up Data

Research exploring the effects of Akis injection primarily focuses on episodes where symptoms become more noticeable, meaning the vast majority of available evidence is restricted to the short-term evaluation of pain and inflammation. Evidence derived from settings with varying symptom burdens provides context on immediate changes, but there is limited information for long-term outcomes or how the use of the injectable formulation might affect the long-term course of a chronic condition.

Common questions about Akis (FAQ)

Q: What should I do if I miss a scheduled dose of Akis?

Akis injection is designed for short-term, acute pain treatment and is administered by a healthcare professional. Because this medication is used for acute needs rather than regular, sustained use, the concept of a 'missed dose' is typically not relevant given the short-term, acute nature of its intended use.

Q: Is Akis addictive or habit-forming?

Akis (diclofenac) is a Nonsteroidal Anti-inflammatory Drug (NSAID). Official regulatory agencies do not classify it as a controlled substance, and product labeling does not indicate a risk of abuse, dependence, or habit formation.

Q: Can Akis injection be used for chronic pain, like arthritis?

Official product information restricts the use of Akis injection to the short-term management of acute pain, typically for no more than two days. Therefore, the injectable formulation's restricted use is not consistent with the management of chronic conditions, such as ongoing arthritis pain.

Q: What should I avoid eating or drinking while using Akis?

Official product information notes an interaction related to alcohol consumption. Regulatory warnings highlight that using this medication with alcohol is associated with a heightened risk of serious adverse events involving the stomach and intestines. No general food-specific restrictions are noted in the product labeling.

The storage and disposal of Akis (Diclofenac solution for injection) must follow specific regulatory conditions to maintain stability and ensure safety.

Disposal must be conducted according to authorized guidelines. The preferred method is using a drug take-back program or a mail-back envelope [Source 2.5]. The medication must not be flushed down the sink or toilet [Source 2.5]. If household disposal is necessary, the drug must be removed from its container, mixed with an undesirable substance (e.g., dirt or coffee grounds), and sealed in a container before being placed in the trash [Source 2.5]. Furthermore, environmental release of the product must be avoided [Source 4.2].